Boryung's Akave will be newly listed

The MOHW, confirmed a partial revision of Criteria for pharmaceutical reimbursed list

Boryung's Akave 30/10mg will be newly listed next month.

 

This drug is a combination of Fimasartan and Atorvastatin.

 

Guerbet Korea's 14 listed pharmaceutical products, such as Lipiodol ultra liquid (Iodized oil), have a lower price.

 

The MOHW confirmed and revised the list of drug benefits and the upper limit.

 

It will take effect from July 1st.

 

The price of 653 items including Boryung's Akave 30/10mg, is automatically calculated and placed on the reimbursed list.

 

Handok Aricept Chong Kun Dang Dilatrend SR cap 16mg Menarini Facpent Nasal Spray Akave 30/10mg is set at ₩902 and Akave 60/10mg at ₩1,013.

 

Handok’s Aricept 23mg is ₩3,952, Chong Kun Dang’s Dilatrend SR 16mg is ₩544, and Menarini’s Facpent nasal spray 100mcg is at ₩43,920.

 

Dong-A ST’s Sivextro 200mg will be removed from the list.

 

The total number of transferable items is 77.

 

The average price of 14 pharmaceutical products including Huon's Zopista 1mg drops by 18.1%.

 

Changes in drug prices in July for added items (cuts)

Guerbet Korea's Lipiodol ultra liquid has a lower price limit from ₩190,000 to ₩133,000, Zopista 1mg is ₩108 to ₩92, Samjin’s Serocover is from ₩603 to ₩590, and Nexpharm Korea’s Cloren is from ₩1,209 to ₩1,004, Jeil's Eldoten is cut from ₩196 to ₩189.

 

PMG’s Rabepran 10mg drops ₩534 to ₩519, Astellas’ Betmiga PR tab 50mg from ₩712 to ₩498, Hanmi’s Ripratin 5mg/ml from ₩371,786 to ₩317,627, Yuhan's Anagre 0.5mg falls from ₩2,748 to ₩2,167, and Shire’s Agrylin 0.5mg falls from ₩2,832 to ₩2,167, respectively.